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Abstract Mastic gum is derived from the tree named Pistacia lentiscus that is grown only in Island Hios of Greek. Since
Mastic was first reported to kill Helicobacter pylori (H. pylori) in 1998, there has been no further study to elucidate which
component of mastic specifically shows the antimicrobial activity against H. pylori. In this study, we examined which
component of mastic gum was responsible for anti-H. pylori activity. We prepared the essential oil of mastic gum and
identified 20 constituents by GC–MS analysis. Ten standard components were assayed for anti-H. pylori activity, and it
clarified that a-terpineol and (E)-methyl isoeugenol showed the anti-H. pylori activity against four different H. pylori
strains that were established from patients with gastritis, gastric ulcer and gastric cancer. These components could be useful
to overcome the drug-resistance H. pylori growth in stomach.
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1 Introduction
Helicobacter pylori (H. pylori), gram-negative bacterium,
induces chronic gastric infection of one-half of the world
population. Infection with H. pylori is often associated with
a viable proportion of duodenal ulcer, gastric ulcer, and
gastric carcinoma [1, 2]. During chronic infection process
of H. pylori for decades, the bacterium infection initially
induces chronic gastritis, and progresses to atrophic
gastritis and metaplasia and then to cancer [3]. Intestinal-
type gastric cancer shows a multi-step carcinogenic pro-
cess, from atrophic gastritis to intestinal metaplasia to
dysplasia. In Japan, Fukase et al. [4] reported that gastric
cancer was inhibited by H. pylori eradication in post-
endoscopic gastric mucosal resection of gastric cancer in a
multi-center randomized control trial. As an approach for
prevention of gastric cancer, H. pylori infection has been
eradicated by combined treatment with several antimicio-
bial agents plus proton pump inhibitors. However, this
approach does not always provide satisfactory benefits for
whole population because of the high cost of therapeutic
agents and the emergence of antibiotic resistance [5]. A
new approach for anti-H. pylori vaccines has seen recently
developed, and some of these vaccines have had some
success in the eradicative animal models, and efforts to
prove these vaccines efficaciens are underway in human
vaccine trials [6].
Further development of potent antimicrobial drugs is
expected to improve the therapeutic and preventive effects
against pathogenesis by H. pylori. Zaidi et al. [7] have
isolated bactericidal constituents from the plant named
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Mallotus philippinenesis that are effective against clari-
thromycin-and metronidazole-resistant strains of Japanese
and Pakistani H. pylori. On the other hand, mastic gum,
which is a resin secreted from the stem of Pistacia lentis-
cus, was found to be effective against H. pylori [8]. In our
present study, we examined which component of the
essential oil prepared from mastic gum could inhibit the
growth of H. pylori. The bactericidal activity of the mastic
components will be discussed in association with their drug
resistance reversal effects.
2 Results and Discussion
2.1 Chemical Composition of the Essential Oil
of Mastic Gum
GC–MS analysis of the essential oil of mastic gum led to
the identification of the components, which are listed in
Table 1. A typical GC–MS chromatogram of the essential
oil of mastic gum is illustrated in Fig. 1. The identification
of the components was based on comparison of their mass
spectra with those of NIST and Wiley libraries, as well as
on comparison of their retention times [9, 10] and of the
standard components analyzed. The major constituent of
the essential oil was a-pinene (Peak 1; 82.26 %), and
totally 20 components were identified from the essential oil
of mastic gum.
2.2 Antibacterial Activity of Mastic Components
We next examined which component inhibits the growth of
H. pylori. Commercially available 10 compounds were
tested for antibacterial activities against H. pylori clinical
strains. The results were summarized in Table 2. Surpris-
ingly, some of them showed antibacterial activity againt
clarithromycin (CAM)- and/or metronidazole (MNZ)-
resistant strains. Figure 2 shows most potent anti-pyloritic
activity of (E)-methyl isoeugenol and a-terpineol not only
against drug sensitive strains (#09-292) but also against drug
resistant strains (#09-87, #09-224 and #09-243). These 10
compounds also showed antibacterial activity against three
different strains (E. coli, S. aureus, B. subtilis) [9].
The antibacterial activity of the mastic gum was first
reported about two decades ago [11]. In 2007, Paraschos
et al. reported that the acidic fraction of mastic gum
showed the potent bactericidal activity against H. pylori
clinical strains and the most active compound was iso-
masticadienolic acid [12]. In our screening analysis of the
essential oil of mastic gum, we identified 20 chemical
compositions, and an (E)-methyl isoeugenol was found to
show the potent antibacterial activity against four H. pylori
strains including CAM- and MNZ-resistant strain. Another
compound, a-terpineol also showed antibacterial activity,
but its effect was less than that of (E)-methyl isoeugenol. In
the previous report [9], verbenone, a-terpineol, and linalool
showed higher antibacterial activity than all other compo-
nents, and (E)-methyl isoeugenol showed moderate activity
against E. coli, S. aureus, B. subtillis. (E)-methyl isoeu-
genol and a-terpineol are the trace components of the
essential oil. However, in our present study, these com-
ponents first showed much higher antibacterial activity
against H. pylori when compared with the same dose of the
essential oil itself.
H. pylori infection is known to be involved in gastric
and duodenum ulcer, gastritis and metaplasia, gastric
cancer and MALT lymphoma [13–17]. H. pylori infection
can be eradicated by combined treatment with several
antimicrobial agents plus proton pump inhibitors. Fukase
et al. have reported that the eradication of H. pylori
reduces the incidence of gastric cancer [4]. In Japan,
combined treatment with proton pump inhibitor (PPI),
amoxicillin (AMPC) and CAM have been applied as first
line eradication therapy, and MNZ is replaced CAM as
second line eradication therapy [18]. However, the sub-
sequent increase in bacterial resistance to CAM in Japan
Table 1 Chemical composition of the essential oil of mastic gum
No. Compound tR (min.) % No. Compound tR (min.) %
1 a-pinene 5.4 82.26 11 a-terpineol 13.8 0.77
2 b-pinene 6.4 2.96 12 p-cymene-8-ol 14.1 0.54
3 b-myrcene 6.7 1.92 13 myrtenal 14.2 0.29
4 p-cymene 7.8 0.41 14 verbenone 14.7 1.50
5 limonene 7.9 0.84 15 (E)-carveol 15.0 0.23
6 linalool 10.4 1.50 16 2-undecanone 17.9 0.16
7 camphenal 11.4 0.31 17 b-caryophyllene 22.7 0.73
8 pinocarvenal 12.0 1.25 18 a-caryophyllene 24.0 0.09
9 verbenol 12.2 0.71 19 (E)-Me isoeugenol 25.6 0.07
10 myrcenol 13.2 0.43 20 caryphyllene oxide 28.5 0.14
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caused a decline in the eradication rate of first line therapy
[19]. Our present study demonstrated antibacterial effects
of (E)-methyl isoeugenol and a-terpineol against CAM-
and MNZ-resistant H. pylori strains (Table 2). These
compounds derived from the mastic gum could be further
useful for eradication of H. pylori including drug-resistant
H. pyroli.
3 Experimental Section
3.1 Material and Chemicals
Mastic gum was purchased from Sunsho Pharmaceutical
Co. Ltd. (Fujinomiya, Japan). Standard compounds, a-
pinene, b-pinene, b-caryophyllene, terpineol were pur-
chased from Sigma Aldrich Japan (Tokyo, Japan), b-myr-
cene, p-cymene, linallol, anethole, verbenone from Wako
Pure Chemical Industries, Ltd. (Osaka, Japan), limonene
and (E)-methyl isoeugenol from Tokyo Chemical Industry
Co. Ltd. (Tokyo, Japan).
3.2 Preparation of the Essential Oil of Mastic Gum
The essential oil was prepared according to the manufac-
tural protocol in the Japanese Pharmacopoeia. Mastic gums
(30 g) in a 300 mL round bottom flask was set to a pre-
scribed distillation apparatus and refluxing with 300 mL of
distilled water for 5 h to yield 0.9 mL of essential oil
(731.2 mg, 2.4 % yield).
3.3 Chemical Composition of the Essential Oil
of Mastic Gum
The GC–MS analysis of the essential oil was undertaken
using a Shimadzu QP-5050A GC–MS system (Kyoto,
Japan), operating in electron ionization (EI) mode with an
ionization energy of 70 eV. The instrument was equipped
with an INERTCAP-5MS/SIL capillary column (30 m,
i.d. 0.25 mm, GL Sciences, Tokyo Japan) with helium as
carrier gas at 1.4 mL/min flow rate. Column temperature
was initially kept for 2 min. at 60 C, gradually increased
to 180 C at a rate of 3.5 C/min then increased to 280 C
at a rate of 10 C/min and kept for 5 min. The injector
and interface were set to 300 and 280 C, respectively,
The gas chromatograph operated in the split mode with a
split ratio of 94:1. The mass spectrum was monitored
starting at m/z 40 and ending at m/z 500, with a scan
Fig. 1 GC–MS chromatogram of the essential oil of mastic gum
Table 2 Antibacterial activity (zones of inhibition, mm) of the
selected compounds of the essential oil of mastic gum
Compounds lg/diska #09-87b #09-224b #09-243b #09-292b
a-pinene 10 – – – –
100 10 12 – 13
b-pinene 10 – – – –
100 – – – –
b-myrcene 10 – – 10 –
100 – – – –
p-cymene 10 – – – –
100 11 11 – –
limonene 10 – – – –
100 11 11 11 12
linalool 10 – – – –
100 15 14 14 14
a-terpineol 10 – – – –
100 17 20 18 22
verbenone 10 – – – –
100 11 11 – 11
b-caryophyllene 10 – – – –
100 12 10 – –
(E)-methyl
isoeugenol
10 – 10 – 15
100 25 23 35 35
essential oil
of mastic gum
10 – – – –
100 – 11 10 –
a Antibacterial activity has not been observed at the dose of 1 lg/disk, and
data were deleted
b #09-87: CAM-sensitive, MNZ-resistant strain; #09-224: CAM-resistant,
MNZ-sensitive strain; #09-243: CAM-resistant, MNZ-resistant strain; #09-292:
CAM-sensitive, MNZ-sensitive strain
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interval of 0.5 s. and threshold of 1000, and the solvent
cut was set to 2 min. The injection volume was 1 lL. The
injection solution was essential oil in acetone (50 % v/v).
The chemical composition of the essential oil was ana-
lyzed using NIST and Wiley registry of mass spectral data
(Shimadzu Corporation).
3.4 H. pylori Clinical Strains
In this study, we used four clinical isolates of H. pylori
which were obtained from patients who underwent endo-
scopic examination at Oita University Hospital, Oita,
Japan. Based on the Epsilometer test (E test) for drug
susceptibility, these strains were assessed as sensitive or
resistant to clarithromycin (CAM) and metronidazole
(MNZ) at minimum inhibitory concentration (MIC) of
1 lg/mL (CAM) and 16 lg/mL or higher (MNZ), respec-
tively. The clinical background and drug sensitivity of the
4 strains were as followed. CAM-sensitive, MNZ-resistant
strain #09-87 derived from atrophic gastritis; CAM-resis-
tant, MNZ-sensitive strain #09-224 from gastric ulcer;
CAM-resistant, MNZ-resistant strain #09-243 from
atrophic gastritis; CAM-sensitive, MNZ-sensitive strain
#09-292 from gastric cancer.
3.5 Antibacterial Activity Test
H. pylori culture suspension was used to inoculate the
plates, and discs containing 1, 10, 100 lg of compounds
were applied onto culture plates. The plates were incubated
under microaerophilic conditions for 3 days at 37 C on
Mueller Hinton II Agar (Becton Dickinson, Franklin Lakes,
NJ, USA) plate supplemented with 7 % horse blood
without antibiotics. The antibacterial activities were eval-
uated by measuring a diameter of the inhibition ring.
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